Please login to the form below

Not currently logged in
Email:
Password:

Bedrock appoints new commercial director

Dr Laura Ciccolini brings experience from the Biopharm Group and Sigma Aldrich

Bedrock Healthcare Communications Dr Laura CiccolinaUK-based medical communications agency Bedrock has appointed Dr Laura Ciccolini to be its new commercial director.

She has over 15 years experience in life sciences and biochemical engineering and previously served as a business development manager for chemical, life science and biotech company Sigma Aldrich.

Her prior roles also include executive director and commercial director at pharma and biotech equipment supplier the Biopharma Group.

In her new senior management position at Bedrock she will be tasked with supporting and driving the agency's growth, working across its insights, med comms and multimedia practices.

Ciccolini will report to CEO David Youds, who said: “I am delighted Laura has joined our team and brings such strong experience.

“Laura will be instrumental in shaping the way we connect with clients and their audiences, as well as providing commercial leadership within the agency to ensure we meet our goals as an organisation.”

21st September 2016

From: Marketing

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...